ZIVOW
Zivo Bioscience, Inc.
Key Financials
Operating Income
$-13361897
↓ 84.0%
Gross Profit
$48952
↑ 321.6%
Revenue
$157220
↑ 468.6%
Net Income
$-13384836
↓ 72.1%
Total Liabilities
$2.2M
↓ 21.9%
EPS (Diluted)
$-4.23
↑ 8.0%
Total Assets
$1.6M
↑ 195.7%
Shareholders' Equity
$-514897.00
↑ 76.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/24/2026 | View on SEC |
| EFFECT | 4/1/2026 | View on SEC |
| 15-12G | 3/31/2026 | View on SEC |
| S-8 POS | 3/31/2026 | View on SEC |
| POS AM | 3/31/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
| 4 | 3/3/2026 | View on SEC |
| SCHEDULE 13D/A | 2/27/2026 | View on SEC |
| 4 | 2/17/2026 | View on SEC |
| 4 | 2/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ZIVOW |
| Company Name | Zivo Bioscience, Inc. |
| CIK | 1101026 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | (248) 452 9866 |